B. Jackson

发表

Survival of Ugandan Infants with Subtype A and D HIV‐1 Infection (HIVNET 012)

P. Musoke, L. Guay, S. Eshleman, 2002, Journal of acquired immune deficiency syndromes.

PHASE III TRIAL OF ANTIBIOTICS TO REDUCE CHORIOAMNIONITIS-RELATED PERINATAL HIV TRANSMISSION A Study of the HIVNET Group Sponsored by: The National Institute of Allergy and Infectious Diseases and the National Institutes of Child Health and Human Development

J. McIntyre, B. Jackson, 1999 .

Psychological Distress and Physical Pain Appear To Have No Short-Term Adverse Impact on Plasma HIV-1 RNA Levels in Patients on Successful HAART

Tara L. Kieffer, R. Siliciano, A. Wu, 2005, HIV clinical trials.

Determinations of Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma: Reassessment of Parameters Affecting Assay Outcome

T. Quinn, L. Mofenson, M. Robb, 1998, Journal of Clinical Microbiology.

Outcomeof Parameters Affecting Assay Plasma: Immunodeficiency Virus Type 1 RNA in Determinations of Levels of Human

T. Quinn, L. Mofenson, M. Robb, 2013 .

Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection

M. Chesney, Wei Huang, D. Donnell, 2007, AIDS.

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

Tara L. Kieffer, Joel E Gallant, Charles Flexner, 2005, JAMA.

Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.

L. Kalish, T. Quinn, J. Lew, 1999, The New England journal of medicine.

Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories

D. Katzenstein, J. Bremer, P. Reichelderfer, 1996, Journal of clinical microbiology.

Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee

S. Hammer, C. Crumpacker, R. D’Aquila, 1993, Journal of clinical microbiology.

The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program.

S. Hammer, D. Katzenstein, A. Collier, 1999, AIDS.

Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.

S. Hammer, D. Katzenstein, M. Hughes, 1998, The Journal of infectious diseases.

Safety, Tolerability, and Antiretroviral Effects of Ritonavir‐Nelfinavir Combination Therapy Administered for 48 Weeks

J. Gallant, C. Flexner, S. Eshleman, 2000, Journal of acquired immune deficiency syndromes.

Comparison of saliva and serum for human immunodeficiency virus type 1 antibody testing in Uganda using a rapid recombinant assay

R. Grant, S. Stramer, P. Kataaha, 1996, Clinical and diagnostic laboratory immunology.

Identification of glycoproteins associated with HIV latently infected cells using quantitative glycoproteomics

Hui Zhang, Weiming Yang, B. Jackson, 2016, Proteomics.

SARS-CoV-2 antibody changes in patients receiving COVID-19 convalescent plasma from normal and vaccinated donors

Anna E. Merrill, K. Rogers, B. Jackson, 2021, Transfusion and Apheresis Science.

A rapid manual method for CD4+ T-cell quantitation for use in developing countries

D. Hom, A. Landay, J. Ho, 1993, AIDS.

Identification of glycoproteins associated with HIV latently infected cells using quantitative glycoproteomics

Hui Zhang, Weiming Yang, B. Jackson, 2016, Proteomics.